Max Planck Institute and Cellomics Announce Collaboration for High Content Screening Development


The Max Planck Institute of Molecular Cell biology and genetics (MPI-CBG), located in Dresden, Germany, and Cellomics, a unit of Fisher Biosciences, recently announced a joint collaboration in the field of High Content Screening (HCS). The institute serves as a hub for numerous academic-industry collaborations in the field of HCS for drug discovery. Cellomics is recognized as the creator of HCS and is the market leader in the field. Cellomics provides a unique cell-based platform for its global clients in pharmaceutical, biotechnology, and academic institutions.

According to Daniel J. Calvo, President of Cellomics, the collaboration objectives include a mix of applications and new product development, as well as establishing a key demonstration center for Europe. "Max Planck is a perfect partner for us," stated Calvo. "They have tremendous experience and capabilities in this area and their strong ties to key academic centers across Europe are a real plus. This collaboration will provide valuable input to help drive the development of our product and applications portfolio for the growing academic market."

As part of the Agreement, MPI-MCBG has purchased the Cellomics' ArrayScan(R) VTI HCS Reader along with its complete portfolio of BioApplications and HCi(TM) informatics software.

Other news from the department science

Most read news

More news from our other portals

Recognise, understand, heal: The World of Diagnostics